Pharmacologic therapy for Peyronie’s disease: what should we prescribe?

Bibliography

• Sommer F, Schwartzer U, Wassmer G, et al. Epidemiology of Peyronie’s disease. Int J Impot Res 2002;14:379-83
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol 2006;175:2115-18
   PubMed Web of Science ®Google Scholar
• DiBenedetti DB, Nguyen D, Zografos L, et al. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol 2011;2011:282503
   PubMedGoogle Scholar
• Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med 2010;7:2359-74
   PubMed Web of Science ®Google Scholar
• Kelly DA. Penises as variable-volume hydrostatic skeletons. Ann N Y Acad Sci 2007;1101:453-63
   PubMedGoogle Scholar
• Brock G, Hsu GL, Nunes L, et al. The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997;157:276-81
   PubMed Web of Science ®Google Scholar
• DiPietro LA. Wound healing: the role of the macrophage and other immune cells. Shock 1995;4:233-40
   PubMed Web of Science ®Google Scholar
• Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair. Int J Mol Med 2000;6:391-407
   PubMed Web of Science ®Google Scholar
• Gelbard M. Myofibroblasts and mechanotransduction: do forces in the tunica albuginea contribute to Peyronie’s disease? J Sex Med 2008;5:2974-6
   PubMedGoogle Scholar
• Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue. Nat Rev Mol Cell Biol 2002;3:349-63
   PubMed Web of Science ®Google Scholar
• Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1β and transforming growth factor-β in peyronie’s plaque fibroblasts. J Urol 2008;179:2447-55
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol 2005;2:291-7
   PubMedGoogle Scholar
• Magee TR, Qian A, Rajfer J, et al. Gene expression profiles in the Peyronie’s disease plaque. Urology 2002;59:451-7
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Vernet D, Magee TR, et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002;6:283-94
   PubMed Web of Science ®Google Scholar
• Valente EG, Vernet D, Ferrini MG, et al. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003;9:229-44
   PubMed Web of Science ®Google Scholar
• Zarafonetis CJ, Horrax TM. Treatment of Peyronie’s disease with potassium para-aminobenzoate (potaba). J Urol 1959;81:770-2
   PubMed Web of Science ®Google Scholar
• Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease; a prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-5
   PubMed Web of Science ®Google Scholar
• Roy J, Carrier S. Acute hepatitis associated with treatment of Peyronie’s disease with potassium paraaminobenzoate (Potaba). J Sex Med 2008;5:2967-9
   PubMedGoogle Scholar
• Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol 2007;178:1398-403
   PubMed Web of Science ®Google Scholar
• Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie’s disease. Int J Impot Res 1999;11:207-12
   PubMed Web of Science ®Google Scholar
• Scott WW, Scardino PL. A new concept in the treatment of Peyronie’s disease. South Med J 1948;41:173-7
   PubMedGoogle Scholar
• Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Biol 1983;9:41-5
   Google Scholar
• Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol 1990;144:1376-9
   PubMed Web of Science ®Google Scholar
• Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie’s disease: therapeutic “rationale” and related emerging treatment strategies. Inflamm Allergy Drug Targets 2012;11:48-57
   PubMedGoogle Scholar
• Inal T, Tokatli Z, Akand M, et al. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology 2006;67:1038-42
   PubMed Web of Science ®Google Scholar
• Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int 2003;91:522-4
   PubMed Web of Science ®Google Scholar
• LaRochelle JC, Levine LA. A survey of primary-care physicians and urologists regarding Peyronie’s disease. J Sex Med 2007;4:1167-73
   PubMed Web of Science ®Google Scholar
• Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie’s disease: a nationwide survey. J Sex Med 2008;5:954-64
   PubMedGoogle Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Colleta AA, Wakefield LM, Howell FV. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Brit J Cancer 1990;62:405-9
   PubMedGoogle Scholar
• Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992;70:648-51
   PubMedGoogle Scholar
• Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-b. Immunol Today 1989;10:258-61
   PubMedGoogle Scholar
• Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999;162:2003-5
   PubMed Web of Science ®Google Scholar
• Armand JP, Ribrag V, Harrousseau JL, et al. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Clin Risk Manag 2007;3:213-24
   PubMedGoogle Scholar
• Byström J. Induration penis plastica. Experience of treatment with procarbazine Natulan. Scand J Urol Nephrol 1976;10:21-5
   PubMed Web of Science ®Google Scholar
• Morgan RJ, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie’s disease. BJU 1978;50:111-13
   Google Scholar
• Fesler MJ, Becker-Koepke S, Di Bisceglie AM, et al. Procarbazine-induced hepatotoxicity: case report and review of the literature. Pharmacotherapy 2010;30:540
   PubMedGoogle Scholar
• Diegelmann RF, Peterkofsky B. Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci USA 1972;69:892-6
   PubMed Web of Science ®Google Scholar
• Ehrlich HP, Bornstein P. Microtubules in transcellular movement of procollagen. Nature 1972;238:257-60
   Google Scholar
• Taylor EW. The mechanism of colchicine inhibition of mitosis. I. Kinetics of inhibition and the binding of H3 colchicine. J Cell Biol 1965;25:145-60
   PubMed Web of Science ®Google Scholar
• Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994;44:291-5
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Tefekli A, Köksal T, et al. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000;12:169-75
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004;16:238-43
   PubMed Web of Science ®Google Scholar
• Bremer J. Carnitine—metabolism and functions. Physiol Rev 1983;63:1420-80
   PubMed Web of Science ®Google Scholar
• Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 2001;88:63-7
   PubMed Web of Science ®Google Scholar
• Shindel AW, Lin G, Ning H, et al. Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 2010;7:2077-85
   PubMed Web of Science ®Google Scholar
• Lin G, Shindel AW, Banie L, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010;7:1787-97
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Asgari MA, Hosseini SY, et al. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int 2010;106:240-8
   PubMed Web of Science ®Google Scholar
• Raetsch C, Jia JD, Boigk G, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002;50:241-7
   PubMed Web of Science ®Google Scholar
• Schandené L, Vandenbussche P, Crusiaux A, et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992;76:30-4
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie’s disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med 2009;6:1743-54
   PubMedGoogle Scholar
• Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res 2010;22:298-309
   PubMedGoogle Scholar
• Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie’s disease with PDE5 inhibitors: a fibrotic strategy. Nat Rev Urol 2010;7:215-21
   PubMed Web of Science ®Google Scholar
• Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 2011;8:1472-7
   PubMed Web of Science ®Google Scholar
• Palmieri A, Imbimbo C, Creta M, et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012;35:190-5
   PubMed Web of Science ®Google Scholar
• Ozturk U, Yesil S, Goktug HN, et al. Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci 2014;183:449-53
   PubMed Web of Science ®Google Scholar
• Gelbard M, Lindner A, Chvapil M, et al. Topical beta-aminopropionitrile in the treatment of Peyronie’s disease. J Urol 1983;129:746-8
   PubMedGoogle Scholar
• Riedl CR, Sternig P, Galle G, et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005;48:656-61
   PubMed Web of Science ®Google Scholar
• Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990;49:463-6
   PubMed Web of Science ®Google Scholar
• Anderson MS, Shankey TV, Lubrano T, et al. Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000;12:S25-31
   PubMedGoogle Scholar
• Fitch WP, Easterling WJ, Talbert RL, et al. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease--a placebo-controlled pilot study. J Sex Med 2007;4:477-84
   PubMed Web of Science ®Google Scholar
• Martin DJ, Badwan K, Parker M, et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002;168:2483-5
   PubMed Web of Science ®Google Scholar
• Levine LA, Estrada CR, Shou W, et al. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003;169:1775-8
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 2004;171:1605-8
   PubMed Web of Science ®Google Scholar
• Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 2007;177:972-5
   PubMed Web of Science ®Google Scholar
• Larsen SM, Levine LA. Review of non-surgical treatment options for Peyronie’s disease. Int J Impot Res 2012;24:1-10
   PubMed Web of Science ®Google Scholar
• Serefoglu EC, Hellstrom WJ. Treatment of Peyronie’s disease: 2012 update. Curr Urol Rep 2011;12:444-52
   PubMedGoogle Scholar
• Chung E, De Young L, Solomon M, et al. Peyronie’s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie’s disease in a cell-culture strain system. J Sex Med 2013;10:1259-67
   PubMed Web of Science ®Google Scholar
• Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 1994;151:1522-4
   PubMed Web of Science ®Google Scholar
• Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 1998;51:620-6
   PubMed Web of Science ®Google Scholar
• Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002;168:621-5
   PubMed Web of Science ®Google Scholar
• Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology 2007;69:1181-4
   PubMed Web of Science ®Google Scholar
• Shirazi M, Haghpanah AR, Badiee M, et al. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009;41:467-71
   PubMed Web of Science ®Google Scholar
• Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease. Urology 2007;69:950-4
   PubMed Web of Science ®Google Scholar
• Gurdal H, Sara Y, Tulunay FC. Effects of calcium channel blockers on formalin-induced nociception and inflammation in rats. Pharmacology 1992;44:290-6
   PubMedGoogle Scholar
• Soh J, Kawauchi A, Kanemitsu N, et al. Nicardipine vs. saline injection as treatment for Peyronie’s disease: a prospective, randomized, single-blind trial. J Sex Med 2010;7:3743-9
   PubMed Web of Science ®Google Scholar
• Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991;25:89-94
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 2006;176:394-8
   PubMed Web of Science ®Google Scholar
• Trost LW, Ates E, Powers M, et al. Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. J Urol 2013;190:2194-9
   PubMed Web of Science ®Google Scholar
• Matsushita O, Koide T, Kobayashi R, et al. Substrate recognition by the collagen-binding domain of Clostridium histolyticum class I collagenase. J Biol Chem 2001;276:8761-70
   PubMed Web of Science ®Google Scholar
• Morales TI, Kuettner KE, Howell DS, et al. Characterization of the metalloproteinase inhibitor produced by bovine articular chondrocyte cultures. Biochim Biophys Acta 1983;760:221-9
   PubMedGoogle Scholar
• Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie’s plaque fibroblasts. J Urol 2008;179:2447-55
   PubMed Web of Science ®Google Scholar
• Syed F, Thomas AN, Singh S, et al. In vitro study of novel collagenase (XIAFLEX®) on Dupuytren’s Disease fibroblasts displays unique drug related properties. PLoS ONE 2012;7:1-22
   Google Scholar
• Gelbard MK, Walsh R, Kaufman J. Collagenase for Peyronie’s disease. Urol Res 1982;10:135-40
   PubMed Web of Science ®Google Scholar
• Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 1993;149:56-8
   PubMed Web of Science ®Google Scholar
• Gelbard M, Hellstrom WJ, Mcmahon CG, et al. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie’s disease. J Sex Med 2013;10:2822-31
   PubMedGoogle Scholar
• Lipshultz L, Goldstein I, Seftel A, et al. Clinical Efficacy of Collagenase Clostridium Histolyticum in the Treatment of Peyronie’s Disease by Subgroups: Results from Two Large, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Studies. BJU Int 2015; doi:10.1111/bju.13096. [Epub ahead of print]
   Google Scholar
• Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207
   PubMed Web of Science ®Google Scholar
• Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s disease. J Sex Med 2012;9:288-95
   PubMed Web of Science ®Google Scholar
• Paulis G, Brancato T, D’ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 cases. Andrology 2013;1:120-8
   PubMed Web of Science ®Google Scholar
• Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie’s disease comparing with pentoxifylline. Glob J Health Sci 2014;18:23-30
   Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie’s disease: a prospective, randomised controlled study. Androl 2014;46:936-42
   PubMed Web of Science ®Google Scholar
• Twidwell J, Levine LA. A new non invasive approach for the treatment of acute phase Peyronie’s disease – A prospective, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of topically applied gel H-100 which combines Nicardipine, Superoxide Dismutase and Emu Oil. Podium Presentation. 20th Annual Fall Scientific Meeting of the Sexual medicine Society of North America; Miami Beach, Miami, FL; 22 November 2014
   Google Scholar
• Lin CS, Lue TF. Adipose-derived stem cells for the treatment of Peyronie’s disease? Eur Urol 2013;63:561-2
   PubMed Web of Science ®Google Scholar
• Castiglione F, Hedlund P, Van der aa F, et al. Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease. Eur Urol 2013;63:551-60
   PubMed Web of Science ®Google Scholar